// App-Quantinova.ai

: Genetic profiling analysis design of well-differentiated aggressive grade 2 and 3 gastroenteropancreatic neuroendocrine tumors in the phase III randomized controlled COMPOSE trial.

Researchers

Presenter

  • Thorvardur Ragnar Halfdanarson

Principal Investigators

  • Jaume Capdevila

  • Daniel M. Halperin

  • Ken Herrmann

  • Grace Kong

  • Simone Leyden

  • Josh Mailman

  • Diane Reidy-Lagunes

  • Rajaventhan Srirajaskanthan

  • Máté Erdö

  • Amanda Rotger

  • Thomas Thevenet

Medical Centers

  • Mayo Clinic, Rochester, MN

  • NeuroEndocrine Cancer Australia, Victoria, Australia

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Norcal Carcinet, Oakland, CA

  • Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging

  • Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, DE

  • Prostate Cancer Theranostics and Imaging Centre of Excellence, Peter MacCallum Cancer Centre

  • Kings College London, London, United Kingdom

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • ITM Oncologics GmbH, Garching/Munich, Germany

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia

Locations

  • United Kingdom

  • Australia

  • United States

  • Germany

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastroenteropancreatic neuroendocrine carcinomas

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Somatostatin

  • Edotreotide

  • Everolimus

  • Oxaliplatin, 5-fluorouracil and folic acid

Outcome

  • N/A

Study Design

  • Randomized

  • Controlled

Phase

  • III

Study Id's

  • NCT04919226

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved